Director International Supply Chain
Viridian Therapeutics
Director International Supply Chain
Viridian Therapeutics
Develops miRNA-targeting therapies for autoimmune diseases
At Viridian, we work with a sense of urgency for patients, creating unity with our team, the industry, and the community. We are committed to using proven science and engineering to improve the lives of people living with serious and rare diseases, and we are getting closer to achieving this goal every day.
Reporting to the Senior Director, Supply Chain, the Director, International Supply Chain will lead the planning and execution of Viridian’s international commercial supply chain, with primary accountability for external supply partners and the labeling, packaging, and delivery of finished goods for markets outside the United States. This individual contributor role will operate with significant autonomy and provide matrix leadership across Supply Chain, External Manufacturing, Quality, Regulatory, Commercial, Finance, and Legal to build launch-ready, compliant, resilient, and scalable supply capabilities.
The successful candidate will translate market and launch requirements into executable supply plans, govern international vendors, anticipate supply risks, and ensure that packaging configurations, country-specific labeling, inventory positioning, and distribution readiness support launch and ongoing commercial supply continuity.
This role is fully remote and based in the UK. Travel to US headquarters or to international meetings may be required at the discretion of management.
Responsibilities (including, but not limited to):
Qualifications:
Applicant Privacy Notice: Information submitted in connection with your application will be processed in accordance with Viridian's Privacy Policy, available here.
Develops miRNA-targeting therapies for autoimmune diseases
Viridian Therapeutics discovers and develops therapies that target microRNA (miRNA) pathways to treat autoimmune diseases, with a focus on thyroid eye disease. The company uses monoclonal antibody technology aimed at the IGF-1 receptor (IGF-1R) pathway to modulate disease biology. Its product approach integrates miRNA biology with antibody engineering to create treatments that intervene in autoimmune processes. The company differentiates itself by combining miRNA-targeting strategies with IGF-1R–focused monoclonal antibodies, operating in the clinical-stage space and concentrating on rare thyroid-related autoimmune conditions. Its goal is to advance clinical candidates through development toward regulatory approval and eventual market launch for patients who suffer from these diseases.
Explore more opportunities at Viridian Therapeutics